Speakers - Boston Symposium 2019

Gautam Agnihotri

Senior Director, Research Service Division

WuXi AppTec

Dr. Gautam Agnihotri has more than 18 years of experience in the pharmaceutical and biotech industry. After graduating with a Ph.D. in Biological Chemistry from the University of Minnesota, Minneapolis, he joined SmithKline Beecham (now GSK) as a post-doctoral scientist in 2000, where he worked in the area of HTS assay development for anti-infective targets. He joined NeoGenesis, Inc. in 2002 where he was part of a group that provided biochemical and cell assay support for external collaborations as well as internal discovery programs.
After NeoGenesis was acquired by Schering-Plough, he joined the HTS group of Schering-Plough in 2006, where he supervised assay development, screening, data analysis, and post-HTS followup for a wide variety of target classes from diverse disease areas in both medium throughput (96/384) and high-throughput (1536) formats.
After the acquisition of Schering-Plough by Merck, Dr. Agnihotri joined the In Vitro Pharmacology group at Merck Research Labs in Kenilworth, NJ in 2010. He led a team in the Biochemistry/Biophysics group to develop assays and determine mode of action for multiple protease targets and then moved to the Screening Operations team in 2012 where he led a team of compound management scientists, automation engineers, and biologists. He left Merck in June 2014 to join WuXi AppTec, and is currently Senior Director in the Research Service Division.
Dr. Agnihotri’s skills span the areas of biochemistry and enzymology, as well as medium and high-throughput screening, automation, data analysis and reporting. In his current role, he helped in the establishment of WuXi AppTec labs in New Jersey and is leading biochemical/biophysical assay development and optimization.

Michael Beluch

Lead, Digital Capability Management, Leads Discovery and Optimization

Bristol-Myers Squibb

Mike Beluch is the Lead Digital Capability Manager for the Leads Discovery & Optimization group at Bristol-Myers Squibb. Mike has worked in the chemical and pharmaceutical industries for 25 years, starting his career at the bench as a Molecular Biologist, specializing for many years in nuclear hormone receptors and cholesterol efflux pathways. In 2004, Mike transitioned to IT at BMS, advancing a 'user-perspective', while working to develop, integrate, and support applications used in Research and Discovery Biology. His responsibilities have been to support existing and emerging technologies in the High-throughput screening group via software development and third-party software integration. In 2019, Mike transitioned to a broader role as a DCM Lead for LDO, responsible for defining strategic technology road-maps and developing solution architectures for new business capabilities.

Johannes H. Voigt

Directory, Computational Chemistry

Foghorn Therapeutics

Johannes Voigt is Director of Computational Chemistry at Foghorn Therapeutics, where he is responsible for ligand and structure based drug design, chemoinformatics, and decision enabling tools. Prior to joining Foghorn, Dr. Voigt contributed to drug discovery projects at Schering-Plough/Merck, Gilead, and CHDI. He is co-author of over 50 publications.

Hetal Patel, M.S.

Senior Scientist, Data II

AbbVie Inc.

Having been at AbbVie for almost 12 Years, Hetal is currently working as a Data Scientist. She has implemented Studies for plate-based screening and creating multiple dashboards and bioassay QC tools using Spotfire. In the past, She has spent 6 years in a high throughput screening group to design and run screens based on biochemical, Cell Based - High Content Analysis, Reporter Gene Assays, GPCR using Tetra assay for all therapeutic areas. Along with running screen she also worked on improving data analysis software with newer enhancement of the internal build software (MAPs). Hetal implemented the first Naive Biologics Library screen at AbbVie. Hetal has worked in a Dermatology group to generate data for candidate selection while bringing new technologies into the group and also worked for Abbott Vascular on Drug Eluting Stent

Request a demonstration or
ask us a question